149510-85-0 Usage
General Description
2,5-Diiodo-4-methylimidazole is a chemical compound with the molecular formula C5H5I2N. It is a derivative of imidazole, containing two iodine atoms and a methyl group attached to the carbon at position 4 of the imidazole ring. 2,5-Diiodo-4-methylimidazole is commonly used in organic synthesis and pharmaceutical research as a building block for the synthesis of various biologically active molecules and pharmaceuticals. It has also been investigated for its potential antimicrobial and antifungal properties, making it a subject of interest for the development of new drugs and treatments. The chemical properties and potential applications of 2,5-Diiodo-4-methylimidazole make it an important compound in the field of medicinal chemistry and pharmaceutical development.
Check Digit Verification of cas no
The CAS Registry Mumber 149510-85-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,9,5,1 and 0 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 149510-85:
(8*1)+(7*4)+(6*9)+(5*5)+(4*1)+(3*0)+(2*8)+(1*5)=140
140 % 10 = 0
So 149510-85-0 is a valid CAS Registry Number.
InChI:InChI=1/C4H4I2N2/c1-2-3(5)8-4(6)7-2/h1H3,(H,7,8)
149510-85-0Relevant articles and documents
Efficient Synthesis of tert-Butyl 2,4-Dialkynylated and 2-Alkynylated-4-Arylated-1H-Imidazole-1-Carboxylate via Regioselective Sonogashira Cross-Coupling Reaction
Jismy, Badr,El Qami, Abdelkarim,Jacquemin, Johan,Guillot, Regis,Tikad, Abdellatif,Abarbri, Mohamed
, p. 4495 - 4507 (2021)
An efficient regioselective cross-coupling reactions of tert-butyl 2,4-dibrominated-5-methyl-1H-imidazole-1-carboxylate is reported. This new synthetic route runs under simple and mild conditions and selectively gives an easy access to 2,4-dialkynylated a
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS
-
Page/Page column 72; 93, (2014/01/18)
Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds.
